Pacific Biosciences of California Inc

The company's capital structure is highly leveraged, with total liabilities of $778.7 million and equity of just $5.35 million, resulting in a debt-to-equity ratio of 120.65. Despite holding $63.7 million in cash and equivalents, the firm's liquidity position is constrained by $645.4 million in long-term debt, leaving net cash negative. Free cash flow has deteriorated to -$530.96 million, and operating cash flow is negative at -$111.21 million, indicating significant cash burn. Profitability metrics are sharply negative, with a return on equity of -102.15% and return on assets of -6.97%. These figures fall well below the industry median for Advanced Medical Equipment & Technology, where positive ROIC and ROE are typically expected. Gross profit of $49.96 million on $160.01 million in revenue yields a 31.2% margin, but this is insufficient to offset operating expenses, which resulted in a $553.86 million loss. The company's revenue is concentrated in a single business model focused on sequencing systems and consumables, with no disclosed geographic diversification in the latest financials. This lack of segment or geographic diversification increases exposure to demand fluctuations in the genomic analysis market. Growth trajectory remains negative, with no revenue history provided to establish a trend. The risk assessment flags liquidity as medium, with dilution risk rated low. However, the firm's negative net cash position and high debt load suggest potential for future dilution if capital raising is required. Recent filings and transcripts highlight ongoing operational losses and capital constraints. Analysts have issued a mean price target of $2.29, with a median of $3.00, and a mean recommendation of 2.5 (leaning toward hold). The firm has not disclosed any material events in the latest period that would suggest a near-term turnaround.